Public Sector Pension Investment Board Takes $2.01 Million Position in BioCryst Pharmaceuticals, Inc. $BCRX

Public Sector Pension Investment Board purchased a new position in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) in the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund purchased 264,800 shares of the biotechnology company’s stock, valued at approximately $2,010,000. Public Sector Pension Investment Board owned 0.13% of BioCryst Pharmaceuticals as of its most recent SEC filing.

Several other hedge funds have also recently made changes to their positions in the stock. Farther Finance Advisors LLC boosted its holdings in BioCryst Pharmaceuticals by 326.8% in the third quarter. Farther Finance Advisors LLC now owns 10,590 shares of the biotechnology company’s stock worth $80,000 after purchasing an additional 8,109 shares during the last quarter. State of Alaska Department of Revenue purchased a new position in shares of BioCryst Pharmaceuticals in the 3rd quarter worth $90,000. Inceptionr LLC purchased a new position in shares of BioCryst Pharmaceuticals in the 2nd quarter worth $107,000. MQS Management LLC bought a new stake in shares of BioCryst Pharmaceuticals in the third quarter worth $99,000. Finally, Choreo LLC purchased a new stake in BioCryst Pharmaceuticals during the second quarter valued at $121,000. 85.88% of the stock is owned by hedge funds and other institutional investors.

BioCryst Pharmaceuticals Trading Down 0.4%

NASDAQ BCRX opened at $7.45 on Monday. BioCryst Pharmaceuticals, Inc. has a 12 month low of $6.00 and a 12 month high of $11.31. The stock has a market cap of $1.57 billion, a price-to-earnings ratio of -149.00 and a beta of 0.83. The company’s 50 day moving average is $7.09 and its two-hundred day moving average is $7.40.

Insider Transactions at BioCryst Pharmaceuticals

In other BioCryst Pharmaceuticals news, insider Alane P. Barnes sold 21,773 shares of the firm’s stock in a transaction dated Monday, December 22nd. The stock was sold at an average price of $7.65, for a total transaction of $166,563.45. Following the sale, the insider directly owned 398,751 shares of the company’s stock, valued at $3,050,445.15. This trade represents a 5.18% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. In the last ninety days, insiders sold 183,453 shares of company stock valued at $1,330,965. Corporate insiders own 5.10% of the company’s stock.

Analyst Upgrades and Downgrades

Several research analysts have issued reports on the company. HC Wainwright raised their target price on BioCryst Pharmaceuticals from $30.00 to $32.00 and gave the stock a “buy” rating in a research report on Monday, December 15th. Zacks Research downgraded shares of BioCryst Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Tuesday, November 4th. Royal Bank Of Canada cut their target price on shares of BioCryst Pharmaceuticals from $14.00 to $13.00 and set an “outperform” rating for the company in a research report on Friday, January 30th. Barclays decreased their price target on shares of BioCryst Pharmaceuticals from $11.00 to $9.00 and set an “equal weight” rating on the stock in a research report on Tuesday, November 4th. Finally, Weiss Ratings reissued a “sell (e+)” rating on shares of BioCryst Pharmaceuticals in a research report on Monday, December 29th. Ten analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, BioCryst Pharmaceuticals currently has an average rating of “Moderate Buy” and a consensus price target of $19.64.

About BioCryst Pharmaceuticals

BioCryst Pharmaceuticals, Inc is a clinical‐stage biotechnology company headquartered in Durham, North Carolina, that focuses on the discovery and development of novel, oral small‐molecule medicines for rare and serious diseases. Since its founding in 1986, the company has leveraged structure‐based drug design to advance a pipeline of targeted therapeutics designed to address underlying disease mechanisms rather than just treat symptoms.

The company’s first commercial product, Orladeyo (berotralstat), is an oral kallikrein inhibitor approved for the prophylactic treatment of hereditary angioedema (HAE) in both the United States and Europe.